Participant outcomes and preferences in Alzheimer's disease clinical trials: The electronic Person-Specific Outcome Measure (ePSOM) development program

INTRODUCTION: Current pharmacological interventions for Alzheimer's dementia delay symptom progression for about a year. Although the outcomes in earlier disease states may include changes in biomarkers, the clinical effectiveness of any intervention can ultimately only be assessed by a patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Saunders, Stina, Muniz-Terrera, Graciela, Watson, Julie, Clarke, Charlotte L., Luz, Saturnino, Evans, Alison R., Ritchie, Craig W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296160/
https://www.ncbi.nlm.nih.gov/pubmed/30581975
http://dx.doi.org/10.1016/j.trci.2018.10.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296160/
https://www.ncbi.nlm.nih.gov/pubmed/30581975
http://dx.doi.org/10.1016/j.trci.2018.10.013

Ejemplares similares